Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...

In interim analysis of phase 2 ASC2ESCALATE trial, patients with chronic-phase chronic myeloid leukemia who fail to respond ...

Congress, Ashley Yocum, PhD, highlights how the Beat AML Master Trial advances safe, personalized treatment and expands targeted therapy options for patients with acute myeloid leukemia (AML).

The lack of therapeutic precision in treatment of myeloid malignancies is in sharp contrast with the fact that myeloid cancers represent the perhaps best characterized cancers of all at the cellular, ...

Revumenib was generally well-tolerated in combination with venetoclax/azacitidine in older, newly diagnosed mNPM1 and KMT2Ar AML patients – – Promising clinical activity and deep responses observed ...

Robust responses observed across subgroups, regardless of co-mutations, number of prior lines of therapy, or prior venetoclax, within efficacy-evaluable pivotal R/R mNPM1 AML population – – 60% (3/5) ...

Join Drs Tania Jain and Rachel Salit as they explore evolving definitions of remission, relapse monitoring, and ...

For the first time in Odisha, the hospital’s department of Clinical Hematology had successfully conducted a Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) on a female patient suffering ...

Chronic Myeloid Leukemia (CML) can be a challenging diagnosis ... Here, we break down the key points about CML, including symptoms, causes, diagnosis, and treatment, to empower you with knowledge and ...

Watch the heart-warming moment a footie-mad teen scores a last minute winner to save his team from relegation on his first ...

Aberrant DNA methylation patterns are a characteristic feature of cancer including myeloid malignancies such as acute myeloid leukemia (AML). The mechanisms behind aberrant DNA methylation have ...

An international clinical trial co-led by Roswell Park Comprehensive Cancer Center has demonstrated that the investigational drug ziftomenib can produce deep, durable responses in people with a ...